Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer

Cancer Research

Volumn 72, Issue 17, 2012, Pages 4574-4586

  Lee, Sangjun ^a   Stewart, Sheila ^a   Nagtegaal, Iris ^b   Luo, Jingqin ^a   Wu, Yun ^c   Colditz, Graham ^a   Medina, Dan ^c   Allred, D Craig ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ENGINEERING; CELL GROWTH; CELL INVASION; CELL MIGRATION; CLUSTER ANALYSIS; CONTROLLED STUDY; CSTA GENE; DST GENE; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FAT1 GENE; FEMALE; GENE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRADUCTAL CARCINOMA; INVASIVE BREAST CANCER; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAMPLE; TMEM45A GENE; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE; CLUSTER ANALYSIS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, SCID; MOLECULAR SEQUENCE ANNOTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865773617     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0636     Document Type: Article

References (44)

1. Allred DC. Biological features of human premalignant breast disease and the progression to cancer. In:Harris JR, Lippman ME, Mlorrow M, Hellman S, Osborne CK, editors. Diseases of the breast. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 323-34.
2. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008;14:370-8.
3. American Cancer Society. Breast cancer facts and figures 2011-2012; p. 2 (Table 1).
4. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 2009;27:279-88.
5. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-200.
6. Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ, editors. Diagnosis and management of ductal carcinoma in situ (DCIS). Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services; 2009.
7. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, et al. State-of-the-Science Conference: diagnosis and management of ductal carcinoma in situ (DCIS). J Natl Cancer Inst 2010;102:161-9.
8. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003;1:362-75.
9. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res 2001;61:5697-702.
10. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003;100:5974-9.
11. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, et al. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res 2004;6:R499-513.
12. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32.
13. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006;8:R61.
14. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006;66:5278-86.
15. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009;11:R7.
16. Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat 2012;133:1009-24.
17. Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 2009;11:R66.
18. Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, et al. Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol 2007;171:252-62.
19. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008;13:394-406.
20. Allred DC, Medina D. The relevance of mouse models to understanding the development and progression of human breast cancer. J Mammary Gland Biol Neoplasia 2008;13:279-88.
21. Ignatoski Km Fau - Lapointe AJ, Lapointe Aj Fau - Radany EH, Radany Eh Fau - Ethier SP, Ethier SP. erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 1999;140:3615-22.
22. Feeley L, Quinn CM. Columnar cell lesions of the breast. Histopathology 2008;52:11-9.
23. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003;9:493-501.
24. Pazolli E, Luo X, Brehm S, Carbery K, Chung JJ, Prior JL, et al. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 2009;69:1230-9.
25. Bauer S, Grossmann S, Vingron M, Robinson PN. Ontologizer 2.0 - a multifunctional tool for GO term enrichment analysis and data exploration. Bioinformatics 2008;24:1650-1.
26. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer 2011;10:15.
27. Hoque MO, Prencipe M, Poeta ML, Barbano R, Valori VM, Copetti M, et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009;18:2694-700.
28. Yoon NK, Seligson DB, Chia D, Elshimali Y, Sulur G, Li A, et al. Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome. Cancer Biomark 2009;5:215-24.
29. Gupta PB, Kuperwasser C. Disease models of breast cancer. Drug Discov Today 2004;1:9-16.
30. Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 2008;10:R87.
31. Emery LA, Tripathi A, King C, Kavanah M, Mendez J, Stone MD, et al. Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol 2009;175:1292-302.
32. Cowin P, Wysolmerski J. Molecular mechanisms guiding embryonic mammary gland development. Cold Spring Harb Perspect Biol 2010;2:a003251.
33. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.
34. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-55.
35. Strojan P, Budihna M, Smid L, Svetic B, Vrhovec I, Kos J, et al. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2000;6:1052-62.
36. Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res 2008;14:5357-67.
37. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, et al. Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate 2001;48:274-84.
38. Zajc I, Sever N, Bervar A, Lah TT. Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Lett 2002;187:185-90.
39. Sonnenberg A, Liem RK. Plakins in development and disease. Exp Cell Res 2007;313:2189-203.
40. Hamill KJ, Hopkinson SB, DeBiase P, Jones JC. BPAG1e maintains keratinocyte polarity through beta4 integrin-mediated modulation of Rac1 and cofilin activities. Mol Biol Cell 2009;20:2954-62.
41. Osada M, Nagakawa Y, Park HL, Yamashita K, Wu G, Kim MS, et al. p63-specific activation of the BPAG-1e promoter. J Invest Dermatol 2005;125:52-60.
42. Hu M, Polyak K. Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer 2008;44:2760-5.
43. Katoh Y, Katoh M. Comparative integromics on FAT1, FAT2, FAT3, and FAT4. Int J Mol Med 2006;18:523-8.
44. Nakaya K, Yamagata HD, Arita N, Nakashiro KI, Nose M, Miki T, et al. Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array. Oncogene 2007;26:5300-8.